KORU Medical Systems, Inc. · NASDAQ:KRMD
KORU Medical Systems — Investor Presentation (November 2026)
15 slides from KORU Medical Systems's investor presentation, November 2026

Slide 1: Freedom to Live Life Fully
Freedom to Live Life Fully A Global Leader in Large- Volume Subcutaneous Drug Delivery Nasdaq: KRMD Corporate Overview November 2026

Slide 2: Forward Looking Statements
Forward Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties. All statements that are not historical fact are forward-looking statements. Forward-looking statements dis

Slide 3: Our Company
Our Company We enable, simplify, and enhance the delivery of large-volume subcutaneous (LVSC) drugs in the home and in the clinic More Time For What Matters Most Capitalizing on the ongoing shift from IV hospital settings to subcutaneous therapy in the home and in infusion clinics KORU Freedom Infus

Slide 4: KORU at a Glance
Our Company KORU at a Glance FY2025 REVENUES $41.1M 75% Domestic Core International Core FREEDOM INTEGRATED INFUSION SYSTEM Pharma Services & Clinical Trials ~60k Global Patients DRUG CLEARANCES / REGISTRATIONS Pharma Services and Domestic & 9 Drugs / 30+ Countries Clinical Trials International Core

Slide 5: KORU's Freedom Infusion System
Our Company KORU’s Freedom Infusion System Mechanical Pumps ~20% of revenues Customizable Consumables ~80% of revenues Simple, Easy-to-use, 97% Patient Customizable Reusable mechanical adherence rate1 platform for use with pump large-volume SC drugs 1. Rutland B, Bosshard J, Southworth C. Enhancing

Slide 6: Global Ig Business Drives Annual Recurring Revenue Base
Our Ig Franchise Global Ig Business Drives Annual Recurring Revenue Base Global Patient Base Current 510(k) Clearances Patients using the KORU Freedom 7 SCIg drugs from 4 major Infusion System today pharmaceutical manufacturers cleared represent 2.7M+ annual recurring for use on the KORU Freedom Inf

Slide 7: Movement of Healthcare from Hospital to the Home Driving Subcutaneous Opportunity
Our Opportunity The Movement of Healthcare from Hospital to the Home Driving Large and Growing Subcutaneous Infusion Opportunity Large-Volume Subcutaneous >10ml Infusion SCIg Opportunity Non-Ig Opportunity2 Growing market with <20% SCIg 95+ New Drugs in penetration (vs IVIg) Development >10 mL 1 7 l

Slide 8: Shift from IV to SC Driving a Sizeable and Growing LVSC Market
Our Opportunity Shift from IV to SC is Driving a Sizeable and Growing Market of Large- Volume Subcutaneous (LVSC) Opportunities Oncology Infusion Pump & Consumables ~$138M 20301 TAM 2 ~$60M 20251 TAM Dosing mL 1 Between 2020-2026, 13 drugs have launched, and the LVSC market has diversified, primaril

Slide 9: Pipeline Opportunities in SCIg and New Drug Therapies
Enabling New Drugs Pipeline Opportunities in SCIg and New Drug Therapies 8 in Pipeline 9 on Label Active Opportunities for New Drugs and Indications 1 Drugs on KORU’s Freedom Infusion System’s Label Commercial Annual Global SCIg 5.4M3 Annual Infusions Drug Asset Infusions Estimate3 Estimated Deferox

Slide 10: Financial Highlights
Financials Financial Highlights YTD 2026 YTD 2025 Y/Y Δ $48M - $48.5M1 $50.0 Revenue $35.4M $30.2M +17% Growth ≈ 19% CAGR (2023-2026) $40.0 Gross Margin 64.0% 62.1% +190bps 13% CAGR OpEx as % Sales 64.1% 70.2% 620 bps improvement $30.0 (2016-2023) 22% Net Loss ($0.3M) ($2.2M) 84% Improvement $20.0 $

Slide 11: Strategically Positioned for Accelerated Growth
Outlook Strategically Positioned for Accelerated Long Term Growth Financial Goals3 Recent Accomplishments1 Strong Fundamentals, $100M revenue Significant Opportunity 1 17% YTD revenue Large and growing market growth over prior year Accelerated for SC drug delivery; ~95 double-digit >10mL drugs in de

Slide 12: Sustained Pathway to +20% Growth CAGR
Outlook Sustained Pathway to +20% Growth Key Growth Drivers +20% New CAGR indications Sustained SCIg market growth International 8-10% annual growth expansion New product innovation & New product launches & innovation share gain Freedom360 TM, Connectivity and 2nd generation consumables $48-$48.5M1

Slide 13: Execution Milestones on Path to Accelerated Revenue Growth
Outlook Execution Milestones on Path to Accelerated Revenue Growth Raising 2026 Financial Guidance • 17-18% revenue growth • Positive Adjusted EBITDA, Cash of >$8M • Gross margin 63-64% Enable More Drugs, Reach More Patients • Add 4 new pipeline collaborations for FY26: 2 of 4 complete • Deferoxamin

Slide 14: Appendix
Appendix

Slide 15: Non-GAAP Financial Measures
Non-GAAP Financial Measures This presentation includes the non-GAAP financial measures “adjusted EPS”, "adjusted diluted EPS“, and “adjusted EBITDA” that are not in accordance with, nor an alternate to, generally accepted accounting principles and may be different from non-GAAP measures used by othe
Source: company website
More decks from KORU Medical Systems, Inc.
Q3 2026 Earnings Presentation15 slides · Nov 10, 2026
Lake Street BIG10 Conference 202618 slides · September 2026
Q2 2026 Earnings Presentation17 slides · Aug 5, 2026
Investor Presentation (August 2026)16 slides · August 2026
Q1 2026 Earnings Presentation14 slides · May 6, 2026
Q4 2025 Earnings Presentation19 slides · Mar 12, 2026